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Chronic periodontitis is the inflammation of the periodontal 
tissues and is characterized by loss of connective tissue 
attachment and alveolar bone.[1,2] This condition commonly 
induced by bacterial plaque, is endemic in all civilized societies, 
and after 40 years of age is the most important reason for 
loss or extraction of teeth, and sometimes predisposing to 
the development of squamous cell carcinoma of the head and 
neck region.[3-5] From the available literature, the therapeutic 
approaches for the treatment of chronic periodontitis are 
categorized into three: Anti-infective treatment designed to 
stop the progression of periodontal tissue loss by the causative 
agent (s); regenerative therapy, which tend to restore structures 
destroyed by the disease, and periodontal tissue maintenance 
therapy, to maintain periodontal stability that is relevant after all 
forms of treatment.[6,7] Consequently, over the years, the focus of 
treatment has been debridement-based treatments such as scaling 
and root planing, flap surgeries, adjunctive use of antibiotics 
systemically (e.g., amoxicillin, metronidazole, ciprofloxacin) 
or locally (e.g., tetracycline, doxycycline, minocycline, 
chlorhexidine, metronidazole), guided tissue regeneration using 
polytetrafluoroethylene membranes, enamel matrix derivative, 
and laser.[8-15] These treatment methods when used in isolation 
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Background: Arthocare forte medication is made up of different constituents and the 
advantages offered by this disposition have not been explored in the management of chronic 
periodontitis. Aim: The aim was to assess the clinical response of bacterial plaque‑induced 
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and bleeding from the pocket after treatment. Statistical analysis was done using EPI INFO 7. 
Results: Majority of the patients were between 46 and 75 years in both control (n = 59/81, 
72.8%) and experimental groups (n = 52/81, 64.2%). There were 86/162 (53.1%) males and 
76/162 (46.9%) females, giving a male‑to‑female ratio of 1.1:1. Seventy‑seven patients (95.1%) 
in the experimental group had total remission in comparison to 32/81 (39.5%) in control group 
which was statistically significant (P < 0.001). Conclusion: The arthocare administered to 
patients in the experimental group speeds up the regenerative capacity and stability of the 
periodontium when compared with the control. Multicentre clinical trials are recommended 
to validate the use of arthocare forte in the treatment of generalized chronic periodontitis.
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or in combination have their shortcomings in clinical dental 
practice but have shown improvement in the patient’s condition 
by reducing clinical attachment loss (CAL) and periodontal 
pocket depths, absence or decreased bleeding on probing the 
periodontal pockets, reduction in tooth mobility and migration, 
and sometimes, this mobility is completely halted due to the 
reattachment of the periodontal tissue fibers to the teeth. Apart 
from halting disease progression and resolving inflammation 
which most of these treatment methods offer, the optimal goal 
of therapy for patients who have lost a significant amount 
of periodontium resulting in teeth mobility and migration is 
regeneration of the lost tissues in order to prevent eventual 
teeth loss is not achieved. However, from the existing literature, 
many variables responsible for complete regeneration of the 
periodontium are unknown.
Arthocare forte with each capsule partly containing 
chondroitin (400 mg) and glucosamine (500 mg) sulfates, is 
a chondro-proctective and anti-arthritic drug that is effective 
in controlling degenerative joint diseases such as rheumatoid 
arthritis, osteoarthritis, osteosclerosis, ankylosing spondylitis, 
and other conditions such as fractures, low back pain, and 
arthritis due to sport injury/active lifestyle. There is paucity 
of literature on the use of this drug in the management of 
these conditions apart from that provided by the manufacturer. 
However, in these circumstances, it is designed to ease 
articular pain, rebuild and rehabilitate damaged cartilage, 
reduce inflammation, and improve patients’ mobility. On the 
contrary, the documented side effects are epigastric distress, 
gastralgia, swollen stomach, loose stool, diarrhea, nausea, 
insomnia, headache, and drowsiness. In addition, glucosamine 
may affect glucose homeostasis, and therefore, have to be used 
with caution in diabetic patients. Furthermore, individuals 
with active peptic ulcer and those on diuretics should use 
glucosamine cautiously as they exhibit lower response.
The basis for this attempt at using arthocare forte medication 
in the management of chronic periodontitis was the 
positive therapeutic effects of its various constituents 
such as glucosamine sulfate potassium, methyl sulfonyl 
methane (MSM), chondroitin sulfate sodium, in the treatment 
of chronic periodontitis and degenerative joint diseases in 
humans.[16-21] To the best of the authors’ knowledge, no study 
has been carried out in the past to determine the effect(s) of 
this drug on the damaged periodontium of the dentition. The 
purpose of this study was to determine whether arthocare forte 
had hoped-for effects on generalized chronic periodontitis, and 
the relationship of age and gender to the prevalence of chronic 
periodontal disease over a period of 5 years.
Subjects and Methods
We carried out a prospective randomized controlled trial that 
clinically evaluated the effect of arthocare forte treatment on 81 
out of 162 patients with teeth mobility as a result of generalized 
chronic periodontitis between July 2008 and June 2013. 
These are consecutive patients at the Dental Surgery Clinic 
of our Tertiary Health Institution who gave informed consent. 
The sample size was calculated using two-arm sample size 
determination formula for statistical superiority design. Ethical 
approval was obtained from the Research Ethics Committee 
of this institution and the study conducted in accordance 
with the Helsinki Declaration of 1975, as revised in 2000. 
All the patients underwent root planing initially out of which 
81/162 (50%) were treated with arthocare for comparative 
analysis. The variables recorded were patient’s age, gender, 
and degree of tooth mobility, periodontal pocket, and bleeding 
from the pocket after treatment.
Inclusion criteria
• Patients above the age of 15 years with one tooth diagnosed in 
their oral cavity as having generalized chronic periodontitis 
with true periodontal pockets induced by bacterial plaque 
and which did not show evidence of clinical or radiological 
involvement of the furcation area in the molar teeth
• No discharge of pus from the periodontal pockets
• Absence of occlusal trauma associated with malocclusion
• Those who kept three post treatment appointments.
Exclusion criteria
• Patients with conditions such as diabetes mellitus, 
peptic ulcer, blood dyscrasias, malnutrition, human 
immunodeficiency virus infection or acquired 
immunodeficiency syndrome
• Pregnant or lactating mothers
• Those on diuretics, steroid, and oral contraceptive therapy
• Admission to usage of tobacco
• Generalized chronic periodontitis due to trauma, and 
multiple teeth involvement
• Those generalized chronic periodontitis associated with 
pseudo-periodontal pockets, and lesions such as tumors, 
cysts, and other allied conditions.
The diagnosis of chronic periodontitis, made by the full-mouth 
examination and recording, was based on the presence of 
tooth mobility, true periodontal pockets, and bleeding of 
the periodontal pockets on probing. The assessment of the 
severity of chronic periodontitis was based on the American 
Academy of Periodontology classification,[22] as revised in 
1999.[23,24] Tooth mobility was scored as M1, M2, and M3 
in the ascending order depending on the severity, whereas 
periodontal pocket was also recorded depending on the CAL 
that was estimated from the bottom of the periodontal pocket to 
the cement-enamel junction at 6 sites per tooth: Mesiobuccal, 
center of buccal, distobuccal, mesiolingual, center of lingual 
and distolingual. The highest depth determined the presence 
or absence of periodontal pocket. Bleeding on probing (BOP) 
with a periodontal probe was determined by indicating sites 
as above that bleed within 30 s of probing. Each patient was 
required to have periapical radiograph of the affected tooth 
before treatment.
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For the comparative analysis, we categorized the patients 
into two groups. Group A (control): Patients were allocated 
to each arm of the study group using computer generated 
numbers. Patients who underwent root planing only and 
B (experimental): Patients that underwent root planing 
in addition to arthocare forte treatment. The treatment 
procedures carried out in both groups on each tooth affected 
by chronic periodontitis were scaling and root planing. This 
procedure was done non-surgically by the combined use of 
hand instruments (Jacquette/hoe scalers, and curettes) and 
ultrasonic scaling devices by the dental therapist and the 
dental surgeon. The patients in both groups were given oral 
hygiene instructions and were also required to use warm saline 
mouth wash 6 times daily spaced out at intervals of 2 h from 
the following day after treatment for 1 week. The subjects 
in the two groups were placed on antibiotics (amoxicillin 
500 mg × 8 h, metronidazole 400 mg × 8 h, for 10 days and 
panadol 1000 mg 8 h for 2 days). The Group B (experimental) 
patients in addition to the above treatment regimen received 
arthocare forte, one tablet × 12 h for 2 weeks as therapeutic 
dose, and then one tablet daily in the subsequent 4 weeks as 
maintenance dose. The subjects were recalled at 1, 3, and 
6 weeks after commencement of treatment. The presence 
of tooth mobility and periodontal pockets, and bleeding on 
probing these pockets were re-assessed clinically in the two 
groups of patients at 6 weeks. Successful treatment was defined 
as the absence of teeth mobility, periodontal pockets, and 
bleeding on clinical examination. The diagnosis and treatments 
in this study were carried out by the same dental surgeon and 
dental therapist, and the study was double blinded.
The variables recorded were patient’s ages, gender, degrees 
of tooth mobility before and after treatment, and periodontal 
pocket/bleeding after treatment. The gain or loss of periodontal 
tissue attachment level was re-assessed clinically by comparing 
probing depth before and after treatment, and by re-evaluating 
bleeding on probing after treatment. Statistical analysis was 
performed using EPI INFO 7, version 0.2.0, 2012 software 
package (CDC, Atlanta, GA, USA). Chi‑square (c2) and 
Student’s t-test were used to compare the degree of mobility. 
The level of significance was set at 0.05 where P < 0.05 is 
considered significant and P > 0.05 non‑significant.
Results
A total of 162 patients underwent routine root planing, out of 
which 81 (experimental group) were treated with arthocare forte, 
and the rest (control group) received nothing. Table 1 shows 
the distribution of age, gender, and degree of mobility of the 
teeth before treatment. Majority of the patients were recorded 
between 46 and 75 years in both Group A (n = 59/81, 72.8%) 
and Group B (n = 52/81, 64.2%). The ages of patients ranged 
from 24 to 81 years with a mean of 47.3 (6.5). In both groups, 
there were 86/162 (53.1%) males and 76/162 (46.9%) females, 
giving a male-to-female ratio of 1.1:1. The degree of teeth 
mobility is shown in Table 1. The severity of teeth mobility 
increased with patient’s age. Table 2 shows the distribution 
of age, gender, and degree of teeth mobility after treatment in 
the two groups. The study shows that the higher the degree of 
teeth mobility before treatment, the less likelihood of complete 
reattachment of the periodontal tissues to the teeth in both the 
control and the experimental groups. In the experimental and 
control groups, those who had successful treatment had their 
periodontal pockets completely obliterated, while those that 
were unsuccessfully treated in the experimental group had 
Table 1: Distribution of age, gender, and degree of teeth 




Gender (n) Total 
(n (%))
Degree of mobility (n)
Male Female M1 M2 M3 Total
Group A
16‑25 2 0 2 (2.5) 2 0 0 2
26‑35 4 2 6 (7.4) 5 1 0 6
36‑45 3 6 9 (11.1) 4 3 2 9
46‑55 15 10 25 (30.9) 7 15 3 25
56‑65 9 12 21 (25.9 10 7 4 21
66‑75 7 6 13 (16.0) 3 3 7 13
76‑85 2 3 5 (6.2) 1 2 2 5
Total 42 39 81 (100.0) 32 31 18 81
Group B
16‑25 1 2 3 (3.7) 2 1 0 3
26‑35 5 3 8 (9.9) 4 3 1 8
36‑45 4 7 11 (13.6) 6 3 2 11
46‑55 13 5 18 (22.2) 9 7 2 18
56‑65 11 9 20 (24.7) 11 5 4 20
66‑75 7 7 14 (17.3) 4 6 4 14
76‑85 3 4 7 (8.6) 1 2 4 7
Total 44 37 81 (100.0) 37 27 17 81










Male Female M1 M2 M3
Group A
16‑25 0 0 0 0 0 0
26‑35 2 0 2 2 0 0
36‑45 3 2 5 2 3 0
46‑55 10 6 16 9 6 1
56‑65 6 8 14 6 6 2
66‑75 4 4 8 3 2 3
76‑85 2 2 4 0 2 2
Total 27 22 49 22 19 8
Group B
16‑25 0 0 0 0 0 0
26‑35 0 0 0 0 0 0
36‑45 0 0 0 0 0 0
46‑55 0 0 0 0 0 0
56‑65 1 1 2 2 0 0
66‑75 1 0 1 1 0 0
76‑85 0 1 1 1 0 0
Total 2 2 4 4 0 0
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residual pocket depths ranging from 1 to 3 mm and those in the 
control group were between 2 and 5 mm. However, the number 
of patients who had successful treatment outcome were greater 
in Group B (n = 77/81, 95.1%) than in A (n = 32/81, 39.5%) 
which was statistically significant (P < 0.001) in favor 
of the experimental group as shown in Table 3. The test 
of significance on the degree of mobility between the 
experimental and control groups was statistically significant 
at all levels of tooth mobility (M1: P <0.001; M2: P <0.001; 
M3: P <0.001) in favor of the experimental group [Table 4]. In 
those patients who did not have successful treatment outcome 
in the two groups (Group A, n = 49/81, 60.5%; Group B, 
n = 4/81, 4.9%), there was decreased teeth mobility relative to 
that at presentation. Furthermore, in this category of patients 
with unsuccessful treatment, periodontal pocketing/bleeding 
persisted in those with M2 and M3 mobility (Group A, 
n = 27/81, 33.3%, Group B, n = 0/81) but not in those with 
M1 mobility. In general, in both groups of patients, those that 
were unsuccessfully treated improved on their periodontal 
attachment level.
In those with unsuccessful treatment outcome in Group A, 
there were 27/49 (33.3%) males and 22/49 (27.2%) females 
with male-to-female ratio of 1.2:1. The age of patients 
ranged from 33 to 81 years with a mean of 58.4 (3.3) years. 
In the experimental group, there were 2/4 (50.0%) males and 
2/4 (50.0%) females with male-to-female ratio of 1:1. The age 
of patients ranged from 63 to 79 years with mean at 69.3 years. 
There was no record of allergic reaction or side effects to the 
drugs used during treatment.
Discussion
From available literature, certain risk factors have been 
associated with the development and progression of chronic 
periodontitis.[24-26] The clinical consequences of some of these 
factors and the side effects of the experimental drug guided the 
exclusion criteria in this study. This study shows that age is 
related to the incidence of periodontal tissue destruction. This 
incidence increases with age, the highest rate occurs between 
50 and 60 years, and gingival recession is the predominant 
lesion before 40 years, while periodontal pocketing is the 
principal mode of destruction between 50 and 60 years 
of age.[26] Unlike previous reports where males were more 
predisposed to this condition, the present study showed almost 
equal gender disposition. This may be due to other confounding 
variables apart from genetics that influence the development 
of this condition.[27,28]
Chronic periodontitis induced by bacterial plaque is 
associated with a variable microbial pattern, but it is initiated 
by Gram‑negative tooth‑associated bio‑film that elicits host 
response resulting in the destruction of the periodontal 
tissues.[29] These anaerobic bacteria microbial films include 
porphyromonas gingivalis, bacteroides forsythus, treponema 
denticola, prevotella intermedia, fusobacterium nucleatum, 
and eubacterium specie.[30] In response to endotoxins derived 
from these periodontal pathogens, several osteoclast-related 
mediators target the destruction of alveolar bone and other 
supporting connective tissue structures like periodontal 
ligament.[29,31] The major drivers of this aggressive 
periodontal tissue destruction are matrix metalloproteinases, 
cathepsins, and other osteoclast-derived enzymes.[1,3,31] The 
extent of the disease progression is influenced adversely 
by the presence of risk factors and the duration of disease 
before patient presents for treatment. These factors directly 
determine the degree of teeth mobility and depth of the 
periodontal pockets formed.
As reported earlier, the scaling and root planing carried 
out in the two groups of patients as treatment modality 
to remove supragingival plaque/calculus and subgingival 
debridement including oral hygiene instructions and use of 
warm saline mouth wash after treatment enhanced healing and 
bacterial plaque control by reducing clinical inflammation, 
periodontal pocket depth, microbial shift to a less pathogenic 
subgingival flora, gain in the clinical attachment level of the 
periodontal tissues and less disease progression.[1,6-8] However, 
the periodontal pocketing/bleeding persisted in 33.3% of 
Group A patients and none was recorded in the experimental 
group. BOP is a very important clinical measurement to assess 
clinical response since its absence can be used as a criterion for 
periodontal tissue stability.[32] Furthermore, from the existing 
literature, the use of antibiotics in the management of chronic 
periodontitis is controversial. However, adjunctive systemic 
antibiotics uses have been shown to offer some advantages to 
the treatment outcome in severe and refractory periodontitis.[1,13] 
Consequently, these groups of patients benefitted from the 
two treatment approaches used in this study. However, the 
beneficial effect was more in the experimental (95.1%) than 
the control (39.5%) group (P < 0.01) which is likely due 
to the effect of arthocare forte medication speeding up the 
regenerative capacity and stability of the periodontium. This 
better treatment outcome in this group may also be due to 
genetic predisposition, lesser age of the patients, and better 
post operative compliance including maintenance of good oral 
Table 3: Test of significance on the success rate between 








Remission 32 (39.5) 77 (95.1) 41.38 <0.001
Nonremission 49 (60.5) 4 (4.9)
Table 4: Test of significance on the degree of mobility 








M1 4.6 (2.9) 0.6 (0.7) <0.001
M2 4.4 (4.8) 0.0 (0.0) <0.001
M3 2.6 (2.3) 0.0 (0.0) <0.001
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hygiene; clinician’s ability to remove sub-gingival deposits, 
and treatment of teeth with less advanced chronic periodontitis.
A capsule of arthocare forte contains glucosamine sulfate 
potassium chloride 500 mg, MSM 250 mg, chondroitin sulphate 
sodium 400 mg, Vitamin E 12.5 mg, manganese sulfate 20 mg, 
bora × 0.5 mg, and selenium dioxide 0.06 mg. According to the 
manufacturer, glucosamine is an amino sugar that stimulates 
chromocytes to synthesize the cartilage building blocks 
and inhibits lysosomal enzymes which degrade cartilage. 
It stabilizes the cell membrane and is an effective inhibitor 
of cyclooxygenase and inflammatory mediators including 
bradykinin, serotonin, and histamine. It was suggested that 
activation of protein kinase C could be one of the mechanisms 
through which glucosamine restores fibrillated cartilage 
chondrocyte adhesion to fibronectin, hence improving the 
repair process in osteoarthritic cartilage.[33] Chondroitin sulfate 
stimulates the synthesis of proteoglycans, hyaluronic acid, and 
inhibits the synthesis of proteolytic enzymes, nitric oxide, and 
other substances that contribute to damage cartilage matrix 
and cause death of chondrocytes. It is used for its flexibility 
in joints and strengthening of muscle. Bassleer et al.[19] noted 
that chondroitin sulfate causes reduction in collagenolytic 
activity and increases matrix component production as it has 
a protective effect on the damaged cartilage, allowing it to 
continue to re-synthesize proteoglycans. Both glucosamine 
and chondroitin are naturally occurring in the human body, but 
can also be extracted from shell‑fish which explains the reason 
for their availability in commercial quantities. MSM is helpful 
in improving joint flexibility, reducing stiffness and swelling, 
improving circulation and cell vitality, reducing pain and scar 
tissue, and in breaking up calcium deposits. MSM is thought to 
work due to sulfur which is believed to strengthen collagen and 
some researchers suggested that it also has anti‑inflammatory 
effects.[21] Vitamin E is an antioxidant, while boron is used as a 
proton donor and manganese acting as a cofactor of enzymes, 
enhances the synthesis of proteoglycans that is needed for the 
formation of cartilage and bone.
It should be noted that inflammatory diseases can occur 
simultaneously at different anatomical sites in the same 
patient, and this sometimes may complicate treatment because 
a medication effective for one disorder may exacerbate the 
other. The anti-arthritic medication dexamethasone, alleviates 
joint disease but can worsen periodontal bone disease, while on 
the other hand, calcitonin had little effect on arthritis but did 
protect against alveolar bone loss in chronic periodontitis.[34,35] 
On the contrary, the anti‑arthritic drug DTrp8‑γMSH (DTrp), 
which acts through the melanocortin (MC) system to reduce 
both arthritic joint inflammation and chronic periodontitis 
is a peptide that simultaneously selectively activates MC3 
receptors which prevents both arthritis and alveolar bone 
loss.[35] This is the gold standard, and thus arthocare forte 
has the same therapeutic spectrum as DTrp, as it has both 
beneficial effects in the treatment of arthritis as well as chronic 
periodontitis.
This study was limited by the inability to estimate the depth 
of the periodontal pockets before treatment, and the follow-up 
period was short. Furthermore, chronic periodontitis involving 
multiple teeth and furcation areas in posterior teeth were 
excluded from the study. It should be noted that the limitations 
of consecutive recruitment of patients include overestimation 
of the pool of available patients who meet the inclusion criteria; 
along with insufficient or untimely patient recruitment.
This study has shown that generalized chronic periodontitis is 
more prevalent in the older age group with males more slightly 
affected than females. The arthocare forte administered to 
patients in the experimental group was of significant benefit 
as it speeds up the regenerative capacity and stability of 
the periodontium more than the control. As this medication 
can be administered safely, multicentre clinical trials are 
recommended to validate its use in the treatment of chronic 
periodontitis.
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